Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01558193
Other study ID # DB-0123-DHAVM
Secondary ID
Status Completed
Phase N/A
First received February 28, 2012
Last updated May 2, 2017
Start date March 2011
Est. completion date July 2011

Study information

Verified date May 2017
Source Swansea University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is a series of well designed studies that have reported, in those with a history of anti-social behavior, that supplementation with vitamins / minerals, omega-3 fatty acids (n-3 FA), or both, reduces the incidence of aggressive behavior. Although there is evidence that all these nutrients have a role, to date the relative contribution of fatty acids and vitamins / minerals has not been considered: for example the possibility of a synergistic interaction has not yet been examined. In addition the topic has to date been studied under real-life condition, such as a prison, making the topic difficult to study. The major aim of the present study was to develop a paradigm that would allow the study of the topic in a sample from the general population without a history of anti-social behavior. Subjects received either a vitamin/mineral supplement, a fatty acid supplement, both or neither for three months, Measures of impulsivity and aggression were assessed before and after supplementation. Although in the past measures of actual behaviour have proved to be sensitive to supplementation, questionnaire measures have not. The second major objective was therefore to consider whether such phenomena can be studied in a sample without a history of anti-social behavior, using standardized, sensitive laboratory based measures and to compare these with questionnaire measures.

POLYMORPHISMS AND THE RESPONSE TO MICRO-NUTRIENT SUPPLLMENTATION The data set were subsequently used to test an a priori hypothesis not related to the initial hypothesis. A meta-analysis found a consistent pattern that micro-nutrient supplementation improved mood (Long SJ, Benton D. Effects of vitamin and mineral supplementation on stress, mild psychiatric symptoms, and mood in nonclinical samples: a meta-analysis. Psychosom Med 2013; 75: 144-153). To produce evidence of possible mechanisms the extent was determined, to which the impact of micro-nutrient supplementation was influenced by a range of polymorphisms associated with neurotransmitter systems known to modulate mood.

The primary outcome measure was the General Health Questionnaire, a 30-item self-report questionnaire that was developed to detect, in a community sample, those who would benefit from seeing a psychiatrist.

Given the literature that relates polymorphisms to mood disorders, and the known pharmacology of anti-depressant drugs, a range of polymorphisms were chosen associated with serotonin and catecholamines.

Dopamine The SNPs associated with the metabolism and functioning of dopamine were: Dopamine beta hydroxylase (DBH, rs16111115); Dopamine transporter (DAT1, rs2550946); Catechol-O-methyltransferase (COMT, rs4680, rs6269). Dopamine receptor D1 (DRD1, rs4532); Dopamine receptor D2 (DRD2, rs1079598, rs1800497); Dopamine receptor D3 (DRD3, rs6280); Dopamine receptor D4 (DRD4, rs1800955).

Serotonin Ten SNPs associated with different aspects of serotonin metabolism were also considered. Rs1843809 is a SNP of the TPH2 gene that encodes Tryptophan hydroxylase. Rs1050565 is a SNP in the BLMH gene that influences the activity of 5HTT (SLC6A4), the serotonin transporter. SNPs associated with various serotonin receptors were also examined: genetic variations of the HTR1A gene (5-HT1A receptor, rs6295); HTR1B gene (5-HT1B receptor, rs6296); HTR2A gene (5-HT2A receptor, rs6311); HTR2B gene (5-HT2B receptor, rs1549339); HTR2C gene (5-hydroxytryptamine receptor 2C, rs518147); HTR3A gene (5-hydroxytryptamine receptor 3A, rs1150226); HTR3B (5-HT3B receptor, rs1672717); HTR4 gene (5-HT4 receptor, rs2278392).

Adrenergic mechanisms Finally six SNPs associated with adrenergic receptors were considered: ADRA2A (adrenoceptor alpha 2A, rs553668); ADRB1 (adrenoceptor alpha B1, rs1801253); ADRB2 (adrenoceptor alpha B2, rs1042713; ADRB3 (adrenoceptor alpha B3, rs4994); SLC6AC (noradrenaline transporter, rs5569 and rs2242447).

Analysis The data will be analyzed using analysis of variance with a change in GHQ from before to after supplementation as the dependent variable: Micronutrient/placebo X Polymorphism.


Description:

Objective: To consider whether aggression and impulsivity respond to multi-vitamins / minerals or fatty acid supplementation and whether there is a synergistic interaction?

In a between subjects design four groups will be contrasted. Those who for three months:

1. Receive two placebos

2. Receive multi-vitamin / mineral plus a placebo

3. Receive fatty acids plus placebo

4. Receive multi-vitamin / mineral plus fatty acids.


Recruitment information / eligibility

Status Completed
Enrollment 202
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Only male participants are being studied of self-reported good health who do not regularly consume seafood. They will be of a minimum age of 18 years of age and a maximum of 35 years of age. They will not be currently taking any medication and have no acute or chronic medical condition

Exclusion Criteria:

- If they had consumed n-3 fatty acid ro vitamin/mineral supplements during the previous six months.

- If they have any history of food intolerance

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
Placebo for DHA of identical appearance - based on olive oil Placebo for vitamins/minerals of identical appearance
Multi-vitamin/mineral
Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
Docosahexaenoic acid
22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
DHA plus vitamins/minerals
The DHA and vitamin/mineral supplements are as above

Locations

Country Name City State
United Kingdom Swansea University Swansea Wales

Sponsors (1)

Lead Sponsor Collaborator
Swansea University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Go Stop Impulsivity Paradigm The GoStop Impulsivity Paradigm measures the ability to inhibit an already initiated response. A number of five digits are presented on a computer screen for 500ms followed by a 500ms blackout. A second number then appears for 500ms followed by a 500ms blackout. If the numbers are identical the mouse button has to be pressed before the second number disappeared. However, the response has to be with-held if a "Stop" signal appeared; that is the second number was identical but changed from black to red. If the two numbers were different then no response was required. Change from before to after supplementation for three months
Primary Rosenzweig Picture Frustration Test This is test of the tendency to respond in an aggressive manner. A series of cartoons are presented that present an intentionally frustrating situation. The participant reports what he or she would say in that situation. Blind the responses are assessed in terms of the extent to which the responses are aggressive in matter
Note that the use of two primary outcomes reflects the aim of the study to contrast performance and questionnaire measures
Change from before to after supplementation for three months
Secondary Buss Perry Aggression Scale The Buss-Perry Aggression Questionnaire assesses four aspects of aggressive behavior: physical aggression, verbal aggression, anger and hostility. Participants rank statements about their temperament using a 7-point Likert scale ranging from 1 (extremely uncharacteristic of me) to 7 (extremely characteristic of me). Change from before to after supplementation for three months
Secondary Perceived Stress Scale The Perceived Stress Scale assesses the extent to which stressful thoughts and feeling had been experienced during the last month. For example: "In the last month, how often have you been upset because of something that happened unexpectedly?" The participant responded on a scale ranging from 0 = Never to 4 = Very Often. An overall score is calculated. Change from before to after supplementation for three months
Secondary Single Key Impulsivity Paradigm A measure of the subjects ability to forgo initial reward for a later larger reward. The subject can choose to wait for a reward and get more points or alternatively respond more quickly and get fewer points sooner. The longer a subject waits the higher the reward; that the more points are earned. A mouse click began the task and a second resulted in a reward. Two counters display the most recent and cumulative reward over a 20 minute session. Subject are able to infer that responses at a faster rate earn smaller rewards. Change from before to after supplementation for three months
Secondary General Health Questionnaire Polymorphisms associated with the metabolism and receptors of dopamine and serotonin will be related to the response to micro-nutrient supplementation Further analysis of existing data - considers changes from baseline to three months
See also
  Status Clinical Trial Phase
Completed NCT02552147 - Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism Phase 1
Completed NCT02485587 - Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents N/A
Active, not recruiting NCT01792167 - Multi-Site Evaluation of Second Step N/A
Completed NCT00361062 - Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment N/A
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00000385 - Long-Term Lithium Treatment for Aggressive Conduct Disorder Phase 3
Not yet recruiting NCT03672942 - Communication Skills vs. Mindfulness for IPV N/A
Recruiting NCT04732052 - The Use of Transcranial Direct Current Stimulation (tDCS) in Adults With Developmental Disabilities N/A
Terminated NCT02483572 - Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control N/A
Completed NCT04097431 - Identifying Precursors to Severe Problem Behavior N/A
Completed NCT04130360 - A Trial of an Online Problem-solving Intervention for Aggression N/A
Completed NCT02563145 - Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents N/A
Completed NCT00510094 - Effectiveness of Treatment for Relational Aggression in Urban African American Girls Phase 3
Recruiting NCT03430973 - Aggressive Driving and Road Rage: A Driving Simulation Experiment. N/A
Completed NCT03693209 - Using Implementation Intentions to Reduce Anger and Aggression in Adolescence N/A
Recruiting NCT05543681 - IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's Phase 2
Completed NCT03784846 - Mindfulness-Based Resilience Training for Aggression, Health, and Stress Among Law Enforcement Officers N/A
Active, not recruiting NCT04204759 - Transcranial Direct Current Stimulation and Antisocial Behavior N/A
Completed NCT06453070 - Hasan Kalyoncu University
Completed NCT01965184 - Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents N/A